ArticleScientific reports2023

Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.

Tomokazu Sazuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.